Share this video  

ASCO 2020 | MINDACT: adjuvant chemotherapy in breast cancer

Emiel Rutgers, MD, PhD, FRCS, Netherlands Cancer Institute, Amsterdam, tells us about the long-term results of the MINDACT study (NCT00433589). This large prospective trial tested the 70-gene signature, MammaPrint, to guide the use of adjuvant chemotherapy in breast cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).